 |
138 Diseases |  |
94 Trials |
|
94 Trials |  |
2090 News |  |
| «12...1920212223242526272829...3233» |
- ||||| Erleada (apalutamide) / J&J
New P2 trial, Combination therapy: SAVE: Radiotherapy Combined With a LHRH (Ant)Agonist Versus Apalutamide in Patients With Biochemical Recurrence After RP (clinicaltrials.gov) - Apr 2, 2019
P2, N=202, Not yet recruiting, Sponsor: Cancer Research Antwerp
- |||| Firmagon (degarelix) / Astellas, Ferring
Trial completion date, Trial primary completion date, Adverse events, Metastases: PRONOUNCE: A Trial Comparing Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Advanced Prostate Cancer and Cardiovascular Disease (clinicaltrials.gov) - Mar 28, 2019
P3, N=900, Recruiting, Sponsor: Ferring Pharmaceuticals
Trial completion date: Dec 2020 --> Jul 2021 | Trial primary completion date: Dec 2020 --> Jul 2021
- ||||| Kisqali (ribociclib) / Novartis
Trial initiation date, Combination therapy, Metastases: CompLEEment-1: Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC (clinicaltrials.gov) - Mar 27, 2019
P3, N=3253, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Trial completion date: Dec 2020 --> Jul 2021 | Trial primary completion date: Dec 2020 --> Jul 2021 Initiation date: Feb 2014 --> Nov 2016
- || Lupron Depot (leuprorelin depot) / AbbVie, Takeda
Proposed mechanism by which KGF and lupron would work if true? (Twitter) - Mar 26, 2019
- ||| Lupron Depot (leuprorelin depot) / AbbVie, Takeda
Now at #EBMT19 @sloan_kettering Christina Cho reporting results of our Ph 2 trial using KGF/Lupron to enhance immune recovery post CD34 selected alloHCT, preclinical work by @vandenBrinkLab @Dudakov_Lab @EnricoVelardi @DrMvandenBrink #bmtsm (Twitter) - Mar 26, 2019
- | orteronel (TAK 700) / Takeda
Trial completion date, Trial primary completion date: Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate Cancer (clinicaltrials.gov) - Mar 14, 2019
P3, N=239, Active, not recruiting, Sponsor: Radiation Therapy Oncology Group
Initiation date: Feb 2014 --> Nov 2016 Trial completion date: Jun 2024 --> Jun 2029 | Trial primary completion date: Jun 2020 --> Jun 2025
- | Erleada (apalutamide) / J&J
Trial completion date, Trial initiation date, Metastases: SOLAR: Systemic and Tumor-Directed Therapy for Oligometastatic Prostate Cancer (clinicaltrials.gov) - Mar 8, 2019
P2, N=28, Recruiting, Sponsor: VA Office of Research and Development
Trial completion date: Jun 2024 --> Jun 2029 | Trial primary completion date: Jun 2020 --> Jun 2025 Trial completion date: Sep 2022 --> Jun 2023 | Initiation date: Dec 2017 --> Jul 2018
- ||| Kisqali (ribociclib) / Novartis
Trial completion date, Combination therapy, Metastases: CompLEEment-1: Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC (clinicaltrials.gov) - Mar 5, 2019
P3, N=3254, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Trial completion date: Sep 2022 --> Jun 2023 | Initiation date: Dec 2017 --> Jul 2018 Trial completion date: Nov 2019 --> May 2021
- | leuprolide acetate for depot suspension / Generic mfg., bicalutamide / Generic mfg.
Trial completion date, Trial primary completion date, Metastases: Cytoreductive Prostatectomy in Treating Patients With Newly Diagnosed, Metastatic Prostate Cancer (clinicaltrials.gov) - Feb 26, 2019
P1, N=26, Active, not recruiting, Sponsor: Rutgers, The State University of New Jersey
Trial completion date: Nov 2019 --> May 2021 Trial completion date: Aug 2018 --> Aug 2019 | Trial primary completion date: Aug 2018 --> Aug 2019
- | Erleada (apalutamide) / J&J
Trial completion date, Trial primary completion date: Apalutamide and Leuprolide in Intermediate and High-risk Prostate Cancer (clinicaltrials.gov) - Feb 20, 2019
P2, N=57, Recruiting, Sponsor: Case Comprehensive Cancer Center
Trial completion date: Aug 2018 --> Aug 2019 | Trial primary completion date: Aug 2018 --> Aug 2019 Trial completion date: Dec 2018 --> Apr 2020 | Trial primary completion date: Dec 2018 --> Apr 2020
- ||||| Kisqali (ribociclib) / Novartis
Enrollment closed, Trial initiation date, Combination therapy, Metastases: CompLEEment-1: Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC (clinicaltrials.gov) - Feb 5, 2019
P3, N=3256, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Trial completion date: Dec 2018 --> Apr 2020 | Trial primary completion date: Dec 2018 --> Apr 2020 Recruiting --> Active, not recruiting | Initiation date: Nov 2016 --> Feb 2014
- |||||| Kisqali (ribociclib) / Novartis
Enrollment open, Combination therapy, Metastases: CompLEEment-1: Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC (clinicaltrials.gov) - Feb 1, 2019
P3, N=3775, Recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting | Initiation date: Nov 2016 --> Feb 2014 Active, not recruiting --> Recruiting
- || Piqray (alpelisib) / Novartis
Trial completion date, Metastases: BYLieve: Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole, Based on Prior Endocrine Therapy, in Patients With PIK3CA Mutant, HR+, HER2- Advanced Breast Cancer Who Have Progressed on or After Prior Treatments (clinicaltrials.gov) - Jan 30, 2019
P2, N=336, Recruiting, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Recruiting Trial completion date: Apr 2020 --> Nov 2020
- | Ibrance (palbociclib) / Pfizer
Trial primary completion date, Metastases: A Phase II Study of Androgen Deprivation Therapy With or Without Palbociclib in RB-Positive Metastatic Prostate Cancer (clinicaltrials.gov) - Jan 29, 2019
P2, N=72, Active, not recruiting, Sponsor: University of Michigan Rogel Cancer Center
Trial completion date: Apr 2020 --> Nov 2020 Trial primary completion date: Jul 2018 --> Sep 2017
- ||| Piqray (alpelisib) / Novartis
Enrollment change, Metastases: BYLieve: Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole, Based on Prior Endocrine Therapy, in Patients With PIK3CA Mutant, HR+, HER2- Advanced Breast Cancer Who Have Progressed on or After Prior Treatments (clinicaltrials.gov) - Jan 23, 2019
P2, N=336, Recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Jul 2018 --> Sep 2017 N=160 --> 336
- ||||| Kisqali (ribociclib) / Novartis
Trial initiation date, Combination therapy, Metastases: CompLEEment-1: Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC (clinicaltrials.gov) - Jan 8, 2019
P3, N=3775, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
N=160 --> 336 Initiation date: Sep 2012 --> Nov 2016
- | docetaxel / Generic mfg.
Trial completion date, Metastases: Docetaxel, Radiation Therapy, and Hormone Therapy in Treating Patients With Locally Advanced Prostate Cancer (clinicaltrials.gov) - Dec 28, 2018
P1, N=20, Active, not recruiting, Sponsor: Medical University of South Carolina
Initiation date: Sep 2012 --> Nov 2016 Trial completion date: Dec 2018 --> Dec 2019
- | leuprolide acetate for depot suspension / Generic mfg.
Enrollment change, Trial completion date, Trial termination, Trial primary completion date: The Relation of GnRH Treatment to QTc Interval in Transgender Females (clinicaltrials.gov) - Dec 26, 2018
P=N/A, N=3, Terminated, Sponsor: University of California, San Francisco
Trial completion date: Dec 2018 --> Dec 2019 N=23 --> 3 | Trial completion date: Jan 2020 --> Aug 2017 | Recruiting --> Terminated | Trial primary completion date: Jun 2019 --> Aug 2017; investigator has left UCSF
- | goserelin acetate / Generic mfg., leuprolide acetate for depot suspension / Generic mfg., bicalutamide / Generic mfg.
Trial completion date, Trial primary completion date: CCRO025: Stereotactic Boost and Long-Term Androgen Deprivation for Adenocarcinoma of the Prostate (clinicaltrials.gov) - Dec 21, 2018
P=N/A, N=29, Recruiting, Sponsor: University of California, Davis
N=23 --> 3 | Trial completion date: Jan 2020 --> Aug 2017 | Recruiting --> Terminated | Trial primary completion date: Jun 2019 --> Aug 2017; investigator has left UCSF Trial completion date: Oct 2018 --> Sep 2019 | Trial primary completion date: Oct 2018 --> Sep 2019
- |||| leuprolide acetate for depot suspension / Generic mfg.
Trial completion: A Study to Assess the Safety and Efficacy of Leuprorelin in Central Precocious Puberty in Chinese Participants (clinicaltrials.gov) - Dec 21, 2018
P4, N=307, Completed, Sponsor: Takeda
Trial completion date: Oct 2018 --> Sep 2019 | Trial primary completion date: Oct 2018 --> Sep 2019 Active, not recruiting --> Completed
- || leuprolide acetate for depot suspension / Generic mfg.
Trial completion date, Trial primary completion date: CRONOS II: Evaluation of Diet and Exercise in Prostate Cancer Patients (clinicaltrials.gov) - Dec 20, 2018
P=N/A, N=1300, Recruiting, Sponsor: AbbVie
Active, not recruiting --> Completed Trial completion date: Jul 2021 --> Aug 2022 | Trial primary completion date: Jul 2021 --> Aug 2022
- | Visanne (dienogest) / Mochida, Bayer
New trial: Comparison of the Operation and Medical Treatment of Endometriosis and Adenomyosis (clinicaltrials.gov) - Dec 19, 2018
P, N=5000, Completed, Sponsor: Taipei Veterans General Hospital, Taiwan
- ||| leuprolide acetate for depot suspension / Generic mfg.
Trial completion, Enrollment change: A Study to Assess the Safety and Efficacy of Enantone (Leuprorelin) in Central Precocious Puberty (CPP) Among Chinese Participants (clinicaltrials.gov) - Dec 5, 2018
P=N/A, N=108, Completed, Sponsor: Takeda
Trial completion date: Jul 2021 --> Aug 2022 | Trial primary completion date: Jul 2021 --> Aug 2022 Recruiting --> Completed | N=300 --> 108
- | leuprolide acetate for depot suspension / Generic mfg.
Phase classification, Enrollment change, Gene Expression Profile, Biopsy: Gene Expression Profile After Gonadotropin Releasing Hormone (GnRH) Agonist Trigger of Oocyte Maturation (clinicaltrials.gov) - Nov 21, 2018
P4, N=7, Terminated, Sponsor: UConn Health
Recruiting --> Completed | N=300 --> 108 Phase classification: P=N/A --> P4 | N=20 --> 7
- | Xtandi (enzalutamide capsule) / Pfizer, Astellas
Trial completion date, Trial primary completion date: Enzalutamide Versus Standard Androgen Deprivation Therapy for the Treatment Hormone Sensitive Prostate Cancer (clinicaltrials.gov) - Nov 15, 2018
P2, N=56, Recruiting, Sponsor: University of Colorado, Denver
Phase classification: P=N/A --> P4 | N=20 --> 7 Trial completion date: Oct 2018 --> Dec 2019 | Trial primary completion date: Oct 2018 --> Mar 2019
- | Orgovyx (relugolix) / Intas, Gedeon Richter, Takeda, ASKA Pharma, Sumitomo Pharma, Pfizer
Trial completion date, Metastases: HERO: A Study to Evaluate the Safety and Efficacy of Relugolix in Men With Advanced Prostate Cancer (clinicaltrials.gov) - Nov 15, 2018
P3, N=1100, Recruiting, Sponsor: Myovant Sciences GmbH
Trial completion date: Oct 2018 --> Dec 2019 | Trial primary completion date: Oct 2018 --> Mar 2019 Trial completion date: Apr 2020 --> Jul 2020
- | Kisqali (ribociclib) / Novartis
Enrollment closed, Trial initiation date, Combination therapy, Metastases: CompLEEment-1: Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC (clinicaltrials.gov) - Nov 8, 2018
P3, N=3258, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Trial completion date: Apr 2020 --> Jul 2020 Recruiting --> Active, not recruiting | Initiation date: Nov 2016 --> Sep 2012
- | goserelin acetate / Generic mfg., leuprolide acetate for depot suspension / Generic mfg., flutamide / Generic mfg.
Trial completion date: Study of External Beam Radiation Therapy With and Without Hormonal Therapy to Treat Prostate Cancer (clinicaltrials.gov) - Nov 5, 2018
P3, N=226, Active, not recruiting, Sponsor: Dana-Farber Cancer Institute
Recruiting --> Active, not recruiting | Initiation date: Nov 2016 --> Sep 2012 Trial completion date: Sep 2018 --> Sep 2019
- | Xtandi (enzalutamide capsule) / Pfizer, Astellas
Trial completion date, Trial primary completion date: Salvage Therapeutic Radiation With Enzalutamide and ADT in Men With Recurrent Prostate Cancer (STREAM) (clinicaltrials.gov) - Nov 2, 2018
P2, N=38, Active, not recruiting, Sponsor: Duke University
Trial completion date: Sep 2018 --> Sep 2019 Trial completion date: Dec 2019 --> Mar 2019 | Trial primary completion date: Dec 2018 --> Mar 2018
- | Yselty (linzagolix) / Kissei, Theramex, Syneos Health
Enrollment closed: Late Phase II Clinical Study of KLH-2109 in Patients With Endometriosis (clinicaltrials.gov) - Oct 31, 2018
P2, N=0, Active, not recruiting, Sponsor: Kissei Pharmaceutical Co., Ltd.
Trial completion date: Dec 2019 --> Mar 2019 | Trial primary completion date: Dec 2018 --> Mar 2018 Recruiting --> Active, not recruiting
- || leuprolide acetate for depot suspension / Generic mfg.
Enrollment open: A Study to Evaluate Leuprolide Acetate 45 mg 6-Month Formulation in Children With Central Precocious Puberty (CPP) (clinicaltrials.gov) - Oct 29, 2018
P3, N=40, Recruiting, Sponsor: AbbVie
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- | valacyclovir / Generic mfg.
Enrollment open, Combination therapy, Surgery, Gene therapy: Phase II High Risk Prostate Cancer Trial Using Gene & Androgen Deprivation Therapies, Radiotherapy, & Surgery (clinicaltrials.gov) - Oct 25, 2018
P2, N=60, Recruiting, Sponsor: The Methodist Hospital System
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- |||| leuprolide acetate for depot suspension / Generic mfg.
New P3 trial: A Study to Evaluate Leuprolide Acetate 45 mg 6-Month Formulation in Children With Central Precocious Puberty (CPP) (clinicaltrials.gov) - Oct 3, 2018
P3, N=40, Not yet recruiting, Sponsor: AbbVie
- | progesterone / Generic mfg., leuprolide acetate for depot suspension / Generic mfg.
Trial completion date, Trial primary completion date: Metabolic Study of Women With Polycystic Ovary Syndrome and Sleep Apnea (clinicaltrials.gov) - Oct 2, 2018
P=N/A, N=80, Active, not recruiting, Sponsor: University of Chicago
Not yet recruiting --> Recruiting Trial completion date: Aug 2017 --> Jan 2019 | Trial primary completion date: Aug 2017 --> Jan 2019
- | Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date: NEOADAPT: NEOADjuvant Aromatase Inhibitor and Pertuzumab/Trastuzumab for Women With Breast Cancer (clinicaltrials.gov) - Sep 28, 2018
P2, N=7, Active, not recruiting, Sponsor: Midwestern Regional Medical Center
Trial completion date: Aug 2017 --> Jan 2019 | Trial primary completion date: Aug 2017 --> Jan 2019 Recruiting --> Active, not recruiting | N=32 --> 7 | Trial completion date: Jul 2018 --> Dec 2018 | Trial primary completion date: Jul 2018 --> Dec 2018
- | leuprolide acetate for depot suspension / Generic mfg.
New P4 trial: Comparative Study Between ICSI Results in Transvaginal Ultrasound Guided Embryo Transfer and Transabdominal Ultrasound Guided Embryo Transfer (clinicaltrials.gov) - Sep 25, 2018
P4, N=120, Not yet recruiting, Sponsor: Cairo University
- | Trial completion, Enrollment change, Trial completion date: Regulation of Cervical Mucus Secretion (clinicaltrials.gov) - Sep 21, 2018
P4, N=7, Completed, Sponsor: Oregon Health and Science University
Recruiting --> Active, not recruiting | N=32 --> 7 | Trial completion date: Jul 2018 --> Dec 2018 | Trial primary completion date: Jul 2018 --> Dec 2018 Active, not recruiting --> Completed | N=10 --> 7 | Trial completion date: Jul 2018 --> Aug 2017
- | tamoxifen / Generic mfg.
New P3 trial: Density Lowering Effect of "OFS Add on to TMX"(DELFINO Trial) (clinicaltrials.gov) - Sep 11, 2018
P3, N=224, Recruiting, Sponsor: Seoul National University Hospital
- ||| leuprolide acetate for depot suspension / Generic mfg.
Trial completion: Special Drug Use Surveillance of Leuprorelin for Injection Kit 22.5 mg in "Premenopausal Breast Cancer" (clinicaltrials.gov) - Sep 10, 2018
P=N/A, N=312, Completed, Sponsor: Takeda
Active, not recruiting --> Completed | N=10 --> 7 | Trial completion date: Jul 2018 --> Aug 2017 Active, not recruiting --> Completed
- | Xtandi (enzalutamide capsule) / Pfizer, Astellas
Trial primary completion date, Combination therapy: Enzalutamide, Radiation Therapy and Hormone Therapy in Treating Patients With Intermediate or High-Risk Prostate Cancer (clinicaltrials.gov) - Aug 25, 2018
P1, N=25, Active, not recruiting, Sponsor: Sidney Kimmel Cancer Center at Thomas Jefferson University
Active, not recruiting --> Completed Trial primary completion date: Dec 2018 --> Jul 2017
- | leuprolide acetate for depot suspension / Generic mfg.
Trial initiation date: GRAET: GnRH Agonist at Embryo Transfer: IVF Outcomes (clinicaltrials.gov) - Aug 17, 2018
P3, N=442, Not yet recruiting, Sponsor: Maimonides Medical Center
Trial primary completion date: Dec 2018 --> Jul 2017 Initiation date: Jul 2018 --> Oct 2018
- ||| leuprolide acetate for depot suspension / Generic mfg.
New trial: Specified Drug-Use Survey of Leuprorelin Acetate Injection Kit 11.25 mg "All-Case Investigation: Spinal and Bulbar Muscular Atrophy (SBMA)" (clinicaltrials.gov) - Aug 13, 2018
P=N/A, N=300, Recruiting, Sponsor: Takeda
- || leuprolide acetate for depot suspension / Generic mfg.
Trial completion date, Trial primary completion date: CRONOS II: Evaluation of Diet and Exercise in Prostate Cancer Patients (clinicaltrials.gov) - Aug 9, 2018
P=N/A, N=1300, Recruiting, Sponsor: AbbVie
Initiation date: Jul 2018 --> Oct 2018 Trial completion date: Aug 2022 --> Jul 2021 | Trial primary completion date: Aug 2022 --> Jul 2021
- || letrozole / Generic mfg., leuprolide acetate for depot suspension / Generic mfg., everolimus / Generic mfg.
Trial completion date, Trial primary completion date: Study of (1) Everolimus, (2) Estrogen Deprivation Therapy (EDT) With Leuprolide + Letrozole and (3) Everolimus + EDT in Patients With Unresectable Fibrolamellar Hepatocellular Carcinoma (FLL-HCC) (clinicaltrials.gov) - Aug 2, 2018
P2, N=84, Active, not recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Trial completion date: Aug 2022 --> Jul 2021 | Trial primary completion date: Aug 2022 --> Jul 2021 Trial completion date: Jul 2018 --> Jul 2019 | Trial primary completion date: Jul 2018 --> Jul 2019
- | Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Trial completion date, Trial primary completion date: NEOADAPT: NEOADjuvant Aromatase Inhibitor and Pertuzumab/Trastuzumab for Women With Breast Cancer (clinicaltrials.gov) - Jul 27, 2018
P2, N=32, Recruiting, Sponsor: Midwestern Regional Medical Center
Trial completion date: Jul 2018 --> Jul 2019 | Trial primary completion date: Jul 2018 --> Jul 2019 Trial completion date: Apr 2018 --> Jul 2018 | Trial primary completion date: Apr 2018 --> Jul 2018
- | Erleada (apalutamide) / J&J
Trial primary completion date: Apalutamide Plus Intermittent Hormone Therapy Versus Intermittent Hormone Therapy Alone in Prostate Cancer (clinicaltrials.gov) - Jul 24, 2018
P2, N=66, Not yet recruiting, Sponsor: Robert J Amato
Trial completion date: Apr 2018 --> Jul 2018 | Trial primary completion date: Apr 2018 --> Jul 2018 Trial primary completion date: Jul 2022 --> Dec 2022
- | leuprolide acetate for depot suspension / Generic mfg.
Enrollment change, Trial completion date, Trial withdrawal, Trial primary completion date: Effect of Short Term Ovarian Suppression on Androgen Overproduction in Overweight Girls With Androgen Excess (clinicaltrials.gov) - Jul 19, 2018
P1, N=0, Withdrawn, Sponsor: University of Virginia
Trial primary completion date: Jul 2022 --> Dec 2022 N=20 --> 0 | Trial completion date: Jun 2020 --> Jul 2018 | Not yet recruiting --> Withdrawn | Trial primary completion date: Jun 2019 --> Jul 2018
- | leuprolide acetate for depot suspension / Generic mfg.
Trial primary completion date: Pilot Study of Leuprolide to Improve Immune Function After Allogeneic Bone Marrow Transplantation (clinicaltrials.gov) - Jul 18, 2018
P2, N=76, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
N=20 --> 0 | Trial completion date: Jun 2020 --> Jul 2018 | Not yet recruiting --> Withdrawn | Trial primary completion date: Jun 2019 --> Jul 2018 Trial primary completion date: Nov 2020 --> Dec 2017
- | Keytruda (pembrolizumab) / Merck (MSD), nelitolimod (SD-101) / TriSalus Life Sci, UT MD Anderson Cancer Center
Enrollment open, Combination therapy, PD(L)-1 Biomarker, Metastases: Pembrolizumab +/- SD-101 in Hormone-Na (clinicaltrials.gov) - Jul 18, 2018
P2, N=42, Recruiting, Sponsor: Lawrence Fong
Trial primary completion date: Nov 2020 --> Dec 2017 Suspended --> Recruiting
- | goserelin acetate / Generic mfg., leuprolide acetate for depot suspension / Generic mfg., docetaxel / Generic mfg.
Trial primary completion date, Surgery: Surgery With or Without Docetaxel and Leuprolide or Goserelin in Treating Patients With High-Risk Localized Prostate Cancer (clinicaltrials.gov) - Jul 10, 2018
P3, N=788, Active, not recruiting, Sponsor: Alliance for Clinical Trials in Oncology
Suspended --> Recruiting Trial primary completion date: Jun 2018 --> Oct 2018